NSCLC, NON-SMALL-CELL LUNG CARCINOMA
Clinical trials for NSCLC, NON-SMALL-CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NSCLC, NON-SMALL-CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NSCLC, NON-SMALL-CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lung cancer combo trial halted early
Disease control TerminatedThis study tested whether adding itacitinib to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. Only 9 people took part before the trial was stopped early. The main goals were to check safety and find the right dose.
Matched conditions: NSCLC, NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Cancer combo study halted early: what we know
Disease control TerminatedThis early-phase study tested a combination of two drugs (atezolizumab and epacadostat) in 29 adults with advanced lung or bladder cancer that had already been treated with chemotherapy. The goal was to check safety and find the right dose. The study was terminated early, so we h…
Matched conditions: NSCLC, NON-SMALL-CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 11, 2026 20:50 UTC